Austar Lifesciences Limited
AULSF
$0.07
$0.071,300.00%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 45.77M | 45.50M | 55.57M | 55.84M | 48.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.77M | 45.50M | 55.57M | 55.84M | 48.40M |
| Cost of Revenue | 36.15M | 35.94M | 44.74M | 44.96M | 38.36M |
| Gross Profit | 9.62M | 9.56M | 10.83M | 10.88M | 10.04M |
| SG&A Expenses | 7.66M | 7.62M | 8.76M | 8.80M | 7.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -607.00K | -603.50K | -1.06M | -1.07M | -739.30K |
| Total Operating Expenses | 44.34M | 44.08M | 54.53M | 54.79M | 47.03M |
| Operating Income | 1.43M | 1.42M | 1.04M | 1.04M | 1.37M |
| Income Before Tax | 2.10M | 2.08M | 833.10K | 837.10K | 634.30K |
| Income Tax Expenses | 462.50K | 459.80K | 180.90K | 181.80K | 345.00K |
| Earnings from Continuing Operations | 1.63M | 1.62M | 652.20K | 655.30K | 289.20K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 95.80K | 95.20K | 56.90K | 57.20K | 116.60K |
| Net Income | 1.73M | 1.72M | 709.10K | 712.50K | 405.80K |
| EBIT | 1.43M | 1.42M | 1.04M | 1.04M | 1.37M |
| EBITDA | 2.44M | 2.42M | 2.18M | 2.19M | 2.33M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 512.58M | 512.58M | 512.58M | 512.58M | 512.58M |
| Average Diluted Shares Outstanding | 512.58M | 512.58M | 512.58M | 512.58M | 512.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |